A comparison of glycine-and ivermectin-mediated conformational changes in the glycine receptor ligand-binding domain by Wang, Qian & Lynch, Joseph W.
 1 
A comparison of glycine- and ivermectin-mediated conformational changes in 
the glycine receptor ligand-binding domain 
 
Qian Wang and Joseph W. Lynch 
 
Queensland Brain Institute and School of Biomedical Sciences, University of Queensland, 
Brisbane, QLD 4072, Australia. 
 
Correspondence: Professor Joseph Lynch, Queensland Brain Institute, University of Queensland, 
Brisbane, QLD 4072, Australia. Tel. +617-3346-6375; Email: j.lynch@uq.edu.au 
 
Keywords: ivermectin, Cys-loop receptor, gating, electrophysiology, voltage-clamp fluorometry. 
 
*Manuscript
 2 
Abstract 
Glycine receptor chloride channels are Cys-loop receptor proteins that isomerize between a 
low affinity closed state and a high affinity ion-conducting state. There is currently much interest in 
understanding the mechanisms that link affinity changes with conductance changes. This essentially 
involves an agonist binding in the glycine receptor ligand-binding site initiating local 
conformational changes that propagate in a wave towards the channel gate. However, it has proved 
difficult to convincingly distinguish those agonist-induced domain movements that are critical for 
triggering activation from those that are simply local deformations to accommodate ligands in the 
site. We employed voltage-clamp fluorometry to compare conformational changes in the ligand-
binding site in response to activation by glycine, which binds locally, and ivermectin, which binds 
in the transmembrane domain. We reasoned that ivermectin-mediated activation should initiate a 
conformational wave that propagates from the pore-lining domain towards the ligand-binding 
domain, eliciting conformational changes in those extracellular domains that are allosterically 
linked to the gate. We found that ivermectin indeed elicited conformational changes in ligand-
binding domain loops C, D and F.  This implies that conformational changes in these domains are 
important for activation. This result also provides a mechanism to explain how ivermectin 
potentiates glycine-induced channel activation.  
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1. Introduction 
 
The glycine receptor (GlyR) chloride channel is a pentameric Cys-loop receptor that 
mediates fast inhibitory neurotransmission in the central nervous system (Lynch, 2009). Individual 
Cys-loop receptor subunits comprise a ligand-binding domain (LBD) and a transmembrane domain 
(TMD). The LBD consists of a 10-strand -sandwich, comprising a six-strand inner -sheet and a 
four-strand outer -sheet (Brejc et al., 2001). Ligand-binding pockets, located at extracellular 
subunit interfaces, are lined by three loops (A, B and C) from the + side of the interface, and three 
-strands (binding ‘loops’ D, E and F) from the - side. The TMD consists of a four -helical 
bundle, with the second transmembrane (TM2) domains contributed by each of the five subunits 
lining a central water-filled pore. Cys-loop receptor channel activation involves structural 
rearrangements that originate at the ligand-binding site and propagate via the extracellular TM2-
TM3 loops to the TM2 domains to create an open channel pore (Bocquet et al., 2009, Hilf and 
Dutzler, 2009, Miyazawa et al., 2003, Unwin, 2005, Zheng and Auerbach, 2011). 
Agonist-binding induces loop C to ‘clasp’ around the bound agonist (Celie et al., 2005, 
Hansen et al., 2005, Mukhtasimova et al., 2005, Unwin et al., 2002, Venkatachalan and 
Czajkowski, 2008). Although molecular dynamics simulations predict that this movement triggers 
channel opening (Law et al., 2005), experimental support for this is lacking to date. Moreover, 
because agonists and antagonists both induce conformational changes in loops C and F, it remains a 
subject of debate as to whether these movements represent local deformations in response to ligand-
binding or whether they also initiate channel activation (Khatri et al., 2009, Khatri and Weiss, 2010, 
Pless and Lynch, 2009, Wang et al., 2010, Zhang et al., 2009, Celie et al., 2005, Thompson et al., 
2006). A new approach is needed to establish whether an allosteric link exists between these ligand-
binding loops and the gate. We reasoned that if the pore can be induced to open without agonist 
occupation of the LBD ligand-binding site, then conformational changes initiated by the opening of 
the pore will propagate from the TM2 domains in reverse to the LBD, eliciting conformational 
changes in those domains that are allosterically linked to the pore gate.   
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Ivermectin is ideal for this purpose as it directly activates both the GlyR and the structurally-
related glutamate-gated chloride channel receptor (GluClR) (Pless et al., 2007, Shan et al., 2001) 
and it has recently been shown to bind in a common TMD location in the GluClR (Hibbs and 
Gouaux, 2011) and the GlyR (Lynagh and Lynch, 2010a, Lynagh et al., 2011). Here we used 
voltage-clamp fluorometry (VCF) to compare glycine- and ivermectin-induced conformational 
changes at 12 fluorescently labeled sites throughout the GlyR LBD. VCF involves covalently 
labeling domains of interest with environmentally-sensitive fluorophores. Because changes in 
fluorophore quantum efficiency occur in response to alterations in their chemical environment, VCF 
reports local ligand-induced conformational changes occurring in real-time at receptor sites of 
interest (Gandhi and Isacoff, 2005, Pless and Lynch, 2008).  
 
2. Materials and methods 
 
2.1. Molecular biology 
The rat 1 GlyR subunit cDNA was subcloned into the pGEMHE expression vector. The 
wild type (WT) and all mutant constructs incorporated the C41A mutation to eliminate the sole 
uncrosslinked extracellular cysteine. QuickChange (Stratagene, La Jolla, CA) was used to generate 
all cysteine mutants used in this study. The successful incorporation of the mutations was confirmed 
by the automated sequencing of the entire coding sequence. Capped mRNA for oocyte injection 
was generated using mMessage mMachine (Ambion, Austin, TX). 
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2.2. Reagents used in VCF experiments 
Sulforhodamine methanethiosulfonate (MTS-R) and 2-((5(6)-tetramethylrhodamine) 
carboxylamino)ethyl methanethiosulfonate (MTS-TAMRA) were obtained from Toronto Research 
Chemicals (North York, ON). Alexa Fluor 546 C5 maleimide (AF546) and tetramethylrhodamine-6-
maleimide (TMRM) were from Invitrogen (Carlsbad, CA). MTS-R, MTS-TAMRA and TMRM 
were dissolved in dimethylsulfoxide and stored at -20°C. AF546 was dissolved directly into ND96 
solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES) on the day of the 
experiment. Ivermectin (Sigma-Aldrich) was stored at -20°C as a 100 mM stock in 
dimethylsulfoxide. 
 
2.3. Oocyte preparation 
Xenopus laevis oocytes (Xenopus Express, France) were prepared as previously described 
(Pless et al., 2007) and injected with 10 ng mRNA. They were then incubated at 18 °C for 3-5 days 
in a solution containing 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, 0.6 
mM theophylline, 2.5 mM pyruvic acid, 50 µg/ml gentamycin, pH 7.4. On the day of recording, 
oocytes were transferred into ND96 containing a 10-20 µM concentration of fluorophore. Typical 
labeling times were 30 s for MTS-R and MTS-TAMRA, 30 min for TMRM and 45 min for AF546. 
Following labeling, oocytes were thoroughly washed in ND96 before use. 
All fluorophores employed here respond with an increase in quantum efficiency as the 
hydrophobicity of their environment is increased (Chang and Weiss, 2002, Dahan et al., 2004). 
Each cysteine mutant was incubated with each of the four fluorophores in turn and generally the 
one yielding the largest glycine-induced fluorescence change (F) was analysed. As unmutated 
GlyRs never exhibited a F or a change in electrophysiological properties following fluorophore 
incubation, we rule out the possibility of labels binding nonspecifically to receptors. 
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2.4. VCF and Data Analysis 
The experimental set up comprised an inverted fluorescence microscope (IX51, Olympus, 
Tokyo, Japan) equipped with a high-Q tetramethylrhodamine isothiocyanate filter set (Chroma 
Technology, Rockingham, VT), a LUCPlanFLN 40x/NA0.6 objective (Olympus), and a 
Hamamatsu H7360-03 photomultiplier (Hamamatsu Photonics, Iwata City, Japan) with a 12 V/100 
W halogen lamp (Olympus) as light source. The recording chamber is similar to those described 
previously (35,36) (Dahan et al., 2004, Pless et al., 2007). Cells were voltage-clamped at -40 mV 
and currents were recorded with an OC-725C oocyte amplifier (Warner, Hamden, CT). Current and 
fluorescence traces were acquired at 200 Hz via a Digidata 1322A interface using pClamp 9.2 
software (Axon Instruments, Union City, CA). Fluorescence signals were digitally filtered at 1-2 Hz 
with an eight-pole Bessel filter for analysis and display. Half-maximal concentrations (EC50) and 
Hill coefficient (nH) values for ligand-induced activation of current and fluorescence were obtained 
using the Hill equation, fitted with a non-linear least squares algorithm (SigmaPlot 9.0, Systat 
Software, Point Richmond, CA). All results are expressed as mean ± S.E.M. of three or more 
independent experiments. Unless otherwise indicated, statistical analysis was performed using 
unpaired Student’s t-test, with p < 0.05 representing significance. 
 
3. Results 
 
We previously identified several extracellular sites that, when covalently labeled with 
environmentally-sensitive fluorophores, elicit robust glycine-induced F responses (Pless et al., 
2007, Pless and Lynch, 2009). Here we compared the peak magnitudes of glycine- and ivermectin-
induced Fs of GlyRs incorporating labels at each of these positions, with and without a mutation 
(A288G) that enhances ivermectin sensitivity by 100-fold (Lynagh and Lynch, 2010b, Lynagh and 
Lynch, 2010a) or a double mutation (A288G-L233W) that converts ivermectin into an inhibitor of 
glycine-gated currents (Lynagh et al., 2011). 
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The following mutations were investigated: H201C and N203C in loop C, Q67C in loop D, 
S121C and L127C in loop E, V178C, A179C and G181C in loop F, E217C, Q219C and G221C in 
the pre-M1 domain and A52C in the  loop. Following labeling as previously described (Pless 
and Lynch, 2009), the A52C, S121C, L127C, A179C, G181C, H201C, E217C, Q219C and G221C 
mutant GlyRs each exhibited robust Fs in response to glycine but exhibited no F response to a 
saturating (30 M) concentration of ivermectin (n = 5 - 10 oocytes each). Fig. 1A-C displays 
sample recordings from MTS-TAMRA-labeled A52C GlyRs, MTS-TAMRA-labeled H201C GlyRs 
and TMRM-labeled E217C GlyRs demonstrating the presence of robust glycine-mediated F 
responses and the absence of ivermectin-mediated F responses.  
In contrast, GlyRs labeled at the Q67C, V178C or N203C positions each produced robust 
Fs in response to both glycine and ivermectin. The experimental approach applied to all three 
mutants is illustrated in Fig. 2. The glycine I EC50, nH and Imax values for unlabeled and MTS-
TAMRA-labeled Q67C-A288G GlyRs are summarised in Table 1. Corresponding values for the 
MTS-TAMRA-labeled Q67C GlyR have previously been published (Pless and Lynch, 2009). We 
were unable to maintain electrophysiological recordings from triple mutant GlyRs for long enough 
to generate full concentration-response relationships. We suspect this was due to their high glycine-
sensitivity. Due to the unavoidably high glycine concentration of the media, this would lead to a 
significant resting chloride flux that may have degraded the viability of the oocytes.  
 A saturating (3 mM) glycine concentration produced much larger Imax and Fmax values 
than those elicited by a saturating (30 M) concentration of ivermectin applied 3 min later (Fig. 
2A). This was not due to incomplete recovery from slow desensitization as glycine responses 
recovered fully within one minute (not shown). A second glycine application applied 3 min after 
ivermectin also elicited reduced Imax and Fmax values, probably due to desensitization or residual 
channel activity resulting from the slowly-reversible ivermectin activation. The labeled Q67C-
A288G GlyR displayed a similar pattern of activity (Fig. 2B), with the major difference being that 
ivermectin exhibited faster channel opening, a proportionately larger Fmax and stronger 
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desensitization. These effects are expected given that A288G dramatically enhances ivermectin 
sensitivity (Lynagh and Lynch, 2010b, Lynagh and Lynch, 2010a). At the Q67C-A288G-L233W 
GlyR, ivermectin activated no detectable I but elicited a robust Fmax (Fig. 2C). The mean Imax 
and Fmax values for all three Q67C-containing GlyRs are presented in Fig. 3A-C. For each mutant, 
the Imax and Fmax values activated by the first glycine application are normalized to one and these 
normalization factors are applied to the respective values induced by ivermectin and the second 
glycine application. It is notable that the ivermectin-mediated Imax and Fmax values are both 
significantly smaller than those induced by the first glycine application for all three mutants. Note, 
however, that the Q67C and Q67C-A288G mutants elicit proportionately very different Fmax 
responses relative to Imax magnitudes, tentatively suggesting that glycine and ivermectin may 
induce different conformational changes. However, it is also evident that ivermectin induces 
different desensitization rates in these two mutants and that glycine and ivermectin generally induce 
distinct desensitization rates at the same mutant. Due to the differing desensitization rates and the 
difficulty in applying agonist solutions rapidly to voltage-clamped oocytes, it is not possible to 
quantitatively compare ivermectin- and glycine-induced Imax and Fmax values, and hence to draw 
inferences concerning possible differences in the conformational changes induced by these agonists. 
Nevertheless, Fig. 3 demonstrates that ivermectin induces detectable conformational changes in the 
vicinity of LBD loop D in both low and high ivermectin affinity GlyRs and in a mutant GlyR where 
ivermectin exhibits only antagonist activity. 
 Fig. 4A-C shows representative recordings from similar experiments performed on the 
AF546-labeled V178C GlyR, the V178C-A288G GlyR and the V178C-A288G-L233W GlyR, 
respectively. Fig. 5A-C summarises the results from these experiments averaged from 3-5 cells each 
and normalised as described above for Fig. 3. Notable differences relative to results presented in 
Fig. 3A-C include the second glycine-activated ΔI max being significantly larger than the first 
glycine-activated ΔI max in the labeled V178C GlyR (Fig. 4A, 5A) and the smaller magnitude of the 
second glycine-activated ΔFmax at all three AF546-labeled V178C mutant constructs (Fig. 5A-C). 
There is no evidence for ivermectin mediating different ΔFmax responses in the three constructs.  
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  Finally, Fig. 6A-C shows examples of results of similar experimental protocols applied to 
the MTS-TAMRA-labeled N203C GlyR, the N203C-A288G GlyR and the N203C-A288G-L233W 
GlyR, respectively. Fig. 7A-C shows averaged results from these experiments averaged from 3-5 
cells each and normalised as described above for Fig. 3. The results are generally consistent with 
those presented in Fig. 3.  
 
4. Discussion  
 
A ligand-induced F implies that the fluorophore microenvironment has been altered by a 
direct fluorophore-ligand interaction, a ligand-induced local conformational change, a ligand-
induced conformational change that propagates to the gate, or any combination of these effects 
(Pless and Lynch, 2009, Wang et al., 2010). A standard assumption that we have employed in this 
study is that if two ligands produce significantly different Fmax values then they report different 
local conformational changes (Khatri et al., 2009, Pless and Lynch, 2009, Wang et al., 2010, Muroi 
et al., 2009). However, the relative magnitudes of Fmax signals are not necessarily directly 
proportional to the magnitude of the conformational changes that produced them. Previous VCF 
studies on the  GlyR showed that an antagonist (strychnine) and an agonist (glycine) produced 
Fmax values of identical magnitude at most labeled sites in loops C and F (Pless and Lynch, 2009). 
The most conservative interpretation of these results is that both ligands produced an identical 
conformational change. Given that loops C and F are located close to the ligand-binding site, it is 
entirely feasible that a common conformational change may have resulted from a local ligand-
induced distension that does not propagate to the gate. However, it is also possible that glycine and 
strychnine induced different conformational changes with the same Fmax at these same sites, with 
only the glycine-induced conformational change being transmitted to the gate. However, it has 
proved difficult to demonstrate this. Consequently, in the present study we adopted a new approach 
to investigate the existence of a direct allosteric linkage between the TMD and the agonist-binding 
loops. 
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The main finding of this study is that ivermectin induced conformational changes in the 
vicinity of V178C in loop F, N203C in loop C and D67C in loop D. Because ivermectin binds in the 
TMD to open the pore (Hibbs and Gouaux, 2011, Lynagh et al., 2011) and loops C, F and D lie in 
the outer and inner -sheets of the LBD, respectively, it is evident that ivermectin induces a global 
receptor conformational change. The principle of reciprocity, which applies to all currently 
proposed mechanisms of agonist action, states simply that if binding affects activation, then 
activation must affect binding (Colquhoun, 1998, Colquhoun and Farrant, 1993). Thus, if the pore 
helices can be moved in a manner to simulate channel activation, this must elicit a conformational 
change that back-propagates to the glycine-binding site to induce conformational changes in those 
LBD domains that are essential for activation and for controlling glycine affinity. In accordance 
with this theory, ivermectin-binding indeed induced a reverse conformational wave that elicited 
conformational changes in loops C, D and F of the glycine-binding site. This implies an allosteric 
linkage between these domains and the TM2, suggesting in turn that agonist-induced 
conformational changes in loops C, D and F may be important for triggering activation. 
In addition to these results, several labeled sites including A52C, S121C, L127C, G181C, 
H201C, E217C, Q219C and G221C showed detectable ΔF responses to glycine but not to 
ivermectin, indicating that ivermectin and glycine induce distinct conformational changes in the 
LBD. This is not surprising given that glycine and ivermectin bind in different locations and 
activate the GlyR via structurally distinct mechanisms (Hibbs and Gouaux, 2011, Pless and Lynch, 
2009, Shan et al., 2001). It is therefore likely that the conformational changes induced in the 
agonist-binding loops by ivermectin are not identical to the glycine-mediated movements that 
trigger activation. Nevertheless, the results demonstrate an allosteric coupling between the pore-
lining -helices and the glycine-binding loops C, F and D.  
 We also found that ivermectin inhibition of the A288G-L233W GlyR is accompanied by 
conformational changes in the same three ligand-binding loops. This implies that ivermectin 
inhibition is also mediated by a global allosteric conformational change that inhibits rather than 
activates the receptor. We speculate that the L233W mutation alters TM2 conformation so that 
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ivermectin closes rather than opens the channel, even though the conformational changes 
ivermectin produces in the LBD may be similar to those associated with opening. 
 Finally, these results also provide a mechanistic basis for understanding how ivermectin 
potentiates glycine-gated currents (Shan et al., 2001) and permits glutamate to bind to the 
structurally-related GluClR (Hibbs and Gouaux, 2011). By altering binding conformation of 
domains lining the agonist-binding site, ivermectin may either facilitate agonist (glycine or 
glutamate) binding or facilitate agonist-induced conformational changes associated with channel 
activation.   
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Table Legend 
 
Table 1. Summary of results for glycine-activated current and fluorescence responses. 
Electrophysiological and fluorescence results are shown in normal and bold type, respectively. 
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Figure Legends 
 
Fig. 1. Examples of labeled mutant GlyRs exhibiting glycine- but not ivermectin-mediated F 
responses.  
In this and subsequent figures, I and F traces are shown in black and red, respectively, and bars 
denote periods of agonist application. Sample recordings for MTS-TAMRA-labeled A52C GlyRs 
(A), MTS-TAMRA-labeled H201C GlyRs (B) and TMRM-labeled E217C GlyRs (C) are shown in 
response to saturating (3 mM) glycine and 30 M ivermectin. 
 
Fig. 2. Examples of glycine- and ivermectin-mediated Fmax responses from MTS-TAMRA-
labeled Q67C-containing GlyRs. 
 A, B and C show examples of glycine- and ivermectin-mediated Fmax responses from MTS-
TAMRA-labeled Q67C, Q67C-A288G and Q67C-A288G-L233W GlyRs, respectively. Agonist 
applications were made at 3 min intervals. 
 
Fig. 3. Comparison of glycine- and ivermectin-mediated Imax and Fmax values at MTS-
TAMRA-labeled Q67C-containing GlyRs. 
‘Glycine1’ denotes the first glycine application and ‘glycine2’ denotes the second. (A) Mean Imax 
and Fmax values for the labeled Q67C GlyR were normalized to one, with the same normalization 
factors applied to responses induced by ivermectin and glycine2. In this and subsequent panels, 
statistical significance is shown relative to glycine1 values. (B, C) Mean Imax and Fmax values for 
the labeled Q67C-A288G and Q67C-A288G-L233W GlyRs, normalized as in (A). * P < 0.05, ** P 
< 0.01 and *** P < 0.001 by unpaired t-test. 
 
Fig. 4. Examples of glycine- and ivermectin-mediated Fmax responses from AF546-labeled 
V178C-containing GlyRs.  
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A, B and C show examples of glycine- and ivermectin-mediated Fmax responses from AF546-
labeled V178C, V178C-A288G and V178C-A288G-L233W GlyRs, respectively. Agonist 
applications were made at 3 min intervals. 
 
Fig. 5. Comparison of glycine- and ivermectin-mediated Imax and Fmax values at AF546-
labeled V178C-containing GlyRs.  
‘Glycine1’ denotes the first glycine application and ‘glycine2’ denotes the second. (A) Mean Imax 
and Fmax values for the labeled V178C GlyR were normalized to one, with the same normalization 
factors applied to responses induced by ivermectin and glycine2. In this and subsequent panels, 
statistical significance is shown relative to glycine1 values. (B, C) Mean Imax and Fmax values for 
the labeled V178C-A288G and V178C-A288G-L233W GlyRs, normalized as in (A). * P < 0.05, ** 
P < 0.01 and *** P < 0.001 by unpaired t-test. 
 
Fig. 6. Examples of glycine- and ivermectin-mediated Fmax responses from MTS-TAMRA-
labeled N203C-containing GlyRs. 
A, B and C show examples of glycine- and ivermectin-mediated Fmax responses from MTS-
TAMRA-labeled N203C, N203C-A288G and N203C-A288G-L233W mutant GlyRs, respectively. 
Agonist applications were made at 3 min intervals. 
 
Fig. 7. Comparison of glycine- and ivermectin-mediated Imax and Fmax values at MTS-
TAMRA-labeled N203C-containing GlyRs. 
‘Glycine1’ denotes the first glycine application and ‘glycine2’ denotes the second. (A) Mean Imax 
and Fmax values for the labeled N203C GlyR were normalized to one, with the same normalization 
factors applied to responses induced by ivermectin and glycine2. In this and subsequent panels, 
statistical significance is shown relative to glycine1 values. (B, C) Mean Imax and Fmax values for 
 16 
the labeled N203C-A288G and N203C-A288G-L233W GlyRs, normalized as in (A). * P < 0.05, ** 
P < 0.01 and *** P < 0.001 by unpaired t-test. 
Highlights: (3-5 bullet points. Maximum 85 characters per bullet point including spaces). 
 
 Agonist-induced conformational changes initiate Cys-loop receptor activation 
 It is difficult to define which conformational changes are critical for activation 
 Ivermectin activates glycine receptors by binding in the transmembrane domain  
 We find ivermectin induces conformational changes in 3 glycine-binding domains 
 This suggests an allosteric linkage between these domains and the gate 
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Table 1. 
 
a - significant difference to unlabeled mutant GlyR (P < 0.05) 
b - significant difference to electrophysiological properties of labeled mutant GlyR (P < 0.05) 
 
 Construct EC50 (μM) nH Imax (μA) Fmax (%) n 
Q67C-A288G 1 GlyR unlabelled 
 
0.6 ± 0.1 3.3 ± 0.2 5.9 ± 0.3 - 4 
Q67C-A288G 1 GlyR MTS-
TAMRA 
2.9 ± 0.5a 0.7 ± 0.1a 10.4 ± 0.4a - 3 
Q67C-A288G 1 GlyR 
MTS-TAMRA 
281 ± 5ab 2.0 ± 0.1ab - 45 ± 2 3 
V178C-A288G 1 GlyR unlabelled 
 
3.8 ± 0.1 1.3 ± 0.1 9.6 ± 0.6 - 3 
V178C-A288G 1 GlyR AF546 
 
3.4 ± 0.7 1.1 ± 0.1 10.2 ± 0.5 - 3 
V178C-A288G 1 GlyR AF546 
 
133 ± 17ab 0.8 ± 0.1ab - 19 ± 3 3 
N203C-A288G 1 GlyR unlabelled 
 
0.7 ± 0.1 2.8 ± 0.2 7.9 ± 0.5 - 4 
N203C-A288G 1 GlyR MTS-
TAMRA 
0.5 ± 0.1 1.5 ± 0.1a 7.5 ± 0.6 - 3 
N203C-A288G 1 GlyR MTS-
TAMRA 
52 ± 8ab 1.2 ± 0.1ab - 25 ± 3 3 
Table 1
